Licensing In Brief
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Merck/Neuromed ink deal for chronic pain agent: Merck acquires Neuromed's lead compound NMED-160 for chronic pain, currently in Phase II, as well as additional agents in the class, under a licensing pact announced March 20. Potentially the first oral N-type calcium channel-blocking pain medication, NMED-160 initial indications will be for chronic pain related to osteoarthritis and lower back pain. Under the deal, Neuromed will receive $25 mil. up-front, plus research costs for at least two years, 100% of late-stage development costs and $202 mil. in milestone payments if NMED-160 is successfully launched for a single indication. If NMED-160 is approved for another indication, and if Neuromed develops another compound that is approved for two indications, Merck will pay an additional $225 mil. NMED-160 is not addictive, and the N-type calcium blocker class is more powerful than opioids and lacks the opioid side effects, Neuromed says...
You may also be interested in...
Licensing In Brief
Pfizer ups ante on Exubera approval with full license: Pfizer's decision to acquire Sanofi-Aventis' marketing rights to Exubera suggests the company is confident that the inhaled insulin product will receive FDA approval. Exubera's user fee date is Jan. 27, following a three-month extension resulting from an FDA request for additional technical chemistry data. Pfizer announced Jan. 12 that it will acquire worldwide rights for the development, production and commercialization of Exubera for $1.3 bil. - building on the firms' previous co-development alliance. The deal follows a judge's ruling that Sanofi's purchase of Aventis constituted a change-in-control under Pfizer and Aventis' 1998 agreement for Exubera. The NDA was submitted in March (1Pharmaceutical Approvals Monthly March 2005, p. 12)...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product